BLAINJECTIONINJECTABLE
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMGALITY (galcanezumab-gnlm) is a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), a key mediator of migraine pathophysiology. It is approved for migraine prophylaxis across episodic migraine, chronic migraine, cluster headache, and other headache disorders. The drug is administered via subcutaneous injection and represents a novel biologic mechanism distinct from traditional preventive agents.
Peak
EMGALITY is at peak lifecycle maturity in a highly competitive CGRP-inhibitor space; teams are stabilized but face ongoing competitive pressure from newer entrants and alternative modalities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Emgality for Migraine in Breastmilk
Started Feb 2024
30 enrolled
Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Started Nov 2020
312 enrolled
Chronic Migraine
The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
Started Aug 2020
25 enrolled
Post-Traumatic Headache
Career Relevance
Working on EMGALITY offers exposure to a mature, competitive biologic franchise in a high-value therapeutic area (migraine prevention). Roles emphasize managed care negotiation, market share defense, and digital/omnichannel engagement to differentiate an injection-based product against preferred oral alternatives.
Worked on EMGALITY at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.